GlassScriptPhysician profile
Warren Christopher Lee
NPI 1942696448
$3,836.14
in general payments reported to CMS, 2019-2025
25 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $228 · 2021: $500 · 2022: $242 · 2023: $488 · 2024: $1,305 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,842 · Education: $24.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,842.23 |
| Education | $24.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $837.16 | 2020-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $720.51 | 2021-2025 | |
| Lilly USA, LLC | $449.30 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $282.48 | 2022-2024 | Freestyle Libre 3 |
| Medtronic, INC. | $213.60 | 2024-2025 | Micra, Minimed 780g |
| Dexcom, INC. | $199.72 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.33 | 2021-2025 | Jardiance |
| Ascendis Pharma Endocrinology INC | $147.99 | 2025 | Yorvipath |
| Amgen INC. | $137.96 | 2024-2025 | Tepezza, Prolia, Evenity |
| Dermavant Sciences, INC. | $107.16 | 2023-2024 | Vtama |
| Glaxosmithkline, LLC. | $79.84 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Alexion Pharmaceuticals, INC. | $77.74 | 2022 | |
| Xeris Pharmaceuticals, INC. | $60.89 | 2024-2025 | Gvoke Hypopen |
| Beta Bionics, INC. | $59.21 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $46.15 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $44.63 | 2024 | |
| Insulet Corporation | $37.49 | 2021-2025 | Omnipod |
| Rhythm Pharmaceuticals, INC. | $27.05 | 2025 | Imcivree |
| Organon LLC | $24.98 | 2025 | Vtama |
| Sequel Med Tech, LLC | $24.92 | 2025 | Twiist |
| Ibsa Pharma INC. | $22.91 | 2025 | Tirosint, Flector, Licart |
| Abbvie INC. | $22.11 | 2021 | |
| Zealand Pharma US, INC. | $22.00 | 2021 | |
| Corcept Therapeutics | $21.28 | 2025 | Korlym |
| Madrigal Pharmaceuticals | $18.73 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.